Challenges to Innovate in the Canadian Biotech Industry

February 24, 2013 at 12:23 pm Leave a comment

One of the key challenges faced by innovators is to develop economic value for their products in the pipeline. With the added burden of increasing regulatory hurdles, today, pharma and biotech companies can spend  2 years to get clearance from organizations such as the CDR (Common Drug Review) and PMPRB (Patented Medicine Price Review Board).

This article describes an  option for biotechnology firms to pool their resources in an innovative R&D model.

Entry filed under: Tools, Treasure from Deep Diving the Biotechnology Web. Tags: , .

An Intriguing Organization

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


biorad1

Bio-Rad Canada has sponsored the development of this site to advance the productivity of the Canadian Biotechnology sector and the fine people who work in it across the country.  We invite readers to contribute content: posters, tools, research and presentations, articles white papers, multimedia, music downloads and entertainment, conference announcements, videos. Please contact info@cbt20.ca for more information.

Bookmark and Share

Site developed by What If What Next(TM)

Follow us on Twitter


%d bloggers like this: